{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Clemastine",
    "query": {
      "intervention": "Clemastine"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 8,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-05T18:15:49.717Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05359653",
      "title": "Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis (MS)",
        "Multiple Sclerosis, Relapsing-Remitting",
        "Multiple Sclerosis, Primary Progressive",
        "Multiple Sclerosis, Chronic Progressive",
        "Multiple Sclerosis Relapse",
        "Multiple Sclerosis Brain Lesion",
        "Multiple Sclerosis Benign"
      ],
      "interventions": [
        {
          "name": "Clemastine Fumarate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 74,
      "start_date": "2023-08-01",
      "completion_date": "2027-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-02",
      "last_synced_at": "2026-09-05T18:15:49.717Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05359653"
    },
    {
      "nct_id": "NCT06591091",
      "title": "Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Depression"
      ],
      "interventions": [
        {
          "name": "Clemastine Fumarate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Illinois at Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2025-12-10",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-06-30",
      "last_synced_at": "2026-09-05T18:15:49.717Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06591091"
    },
    {
      "nct_id": "NCT06065670",
      "title": "Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a Myelin Repair Therapy",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Demyelinating Diseases",
        "Demyelination; Corpus Callosum",
        "Multiple Sclerosis Brain Lesion",
        "Multiple Sclerosis Acute and Progressive",
        "Clinically Isolated Syndrome, CNS Demyelinating"
      ],
      "interventions": [
        {
          "name": "Clemastine Fumarate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 44,
      "start_date": "2026-09-15",
      "completion_date": "2028-10-30",
      "has_results": false,
      "last_update_posted_date": "2026-03-11",
      "last_synced_at": "2026-09-05T18:15:49.717Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06065670"
    },
    {
      "nct_id": "NCT07688746",
      "title": "Neonatal White Matter Injury Trial (WRAP)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "White Matter Injury",
        "Brain Injury, Fetus and Neonate",
        "Neonatal Brain Injury",
        "Periventricular Leukomalacia",
        "Periventricular White Matter Abnormalities"
      ],
      "interventions": [
        {
          "name": "Clemastine fumarate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bridget LaMonica Ostrem, M.D., Ph.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Weeks",
        "maximum_age": "20 Weeks",
        "sex": "ALL",
        "summary": "3 Weeks to 20 Weeks"
      },
      "enrollment_count": 24,
      "start_date": "2026-07-26",
      "completion_date": "2031-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-28",
      "last_synced_at": "2026-09-05T18:15:49.717Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07688746"
    },
    {
      "nct_id": "NCT02040298",
      "title": "Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis, Relapsing-Remitting"
      ],
      "interventions": [
        {
          "name": "Clemastine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 50,
      "start_date": "2014-01",
      "completion_date": "2016-04",
      "has_results": true,
      "last_update_posted_date": "2025-09-17",
      "last_synced_at": "2026-09-05T18:15:49.717Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02040298"
    },
    {
      "nct_id": "NCT07304024",
      "title": "A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Central Auditory Processing Disorder",
        "Hearing Impaired (Partially)",
        "Hearing",
        "Hearing Abnormality",
        "Hearing Disability",
        "Hearing Disorder",
        "Hearing Disorders",
        "Hearing Impairment, Sensorineural",
        "Hearing Handicap",
        "Hearing Impaired",
        "Hearing Impairment",
        "Hearing Loss",
        "Central Auditory Disease",
        "Noise Exposure",
        "Noise Induced Hearing Loss",
        "Noise-Induced Hearing Loss",
        "Sound Perception",
        "Myelin Degeneration",
        "Myelinopathy",
        "Myelin Integrity",
        "Remyelination",
        "Hidden Hearing Loss",
        "Cocktail Party Skill",
        "Cocktail Party Syndrome",
        "CAPD",
        "Age Problem"
      ],
      "interventions": [
        {
          "name": "Clemastine Fumarate Combined With Engineered Sound",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Clemastine Fumarate Combined With Pink Noise",
          "type": "DRUG"
        },
        {
          "name": "Placebo Drug With Engineered Sound",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo - Placebo",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "45 Years to 65 Years"
      },
      "enrollment_count": 344,
      "start_date": "2025-03-31",
      "completion_date": "2028-07",
      "has_results": false,
      "last_update_posted_date": "2026-04-30",
      "last_synced_at": "2026-09-05T18:15:49.717Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07304024"
    },
    {
      "nct_id": "NCT02521311",
      "title": "Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Optic Neuritis"
      ],
      "interventions": [
        {
          "name": "Clemastine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 90,
      "start_date": "2017-02-28",
      "completion_date": "2028-08",
      "has_results": false,
      "last_update_posted_date": "2026-03-11",
      "last_synced_at": "2026-09-05T18:15:49.717Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02521311"
    },
    {
      "nct_id": "NCT02613091",
      "title": "Effect of Clemastine Fumarate on Color Vision in Healthy Controls",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Subjects"
      ],
      "interventions": [
        {
          "name": "Clemastine fumarate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 23,
      "start_date": "2016-04",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2016-11-03",
      "last_synced_at": "2026-09-05T18:15:49.717Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02613091"
    }
  ]
}